Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs
admin 5th December 2017 Uncategorised 0Depomed is selling off the franchise that was once the center of its growth hopes, and plenty of the company’s employees are leaving with it. Less than three years after shelling out $1.05 billion to acquire Nucynta ER and XR from Johnson & Johnson, the California drugmaker has licensed the meds to Collegium Pharmaceutical for just $10 million upfront.
More: Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs
Source: fierce